NCT04796064已完成不适用
Comparative Effectiveness Study of Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 Sarcopenia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 76
- 试验地点
- 2
- 主要终点
- Handgrip strength
研究概览
简要总结
Sarcopenia is the major health concern and common consequence of COVID-19 in the ageing population. The objective of this study is to find and compare low and high-intensity aerobic training protocols on clinical and psychological effects in community-dwelling older men with post-COVID 19 Sarcopenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 60 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Age range of 60 - 80 years with
- •A positive diagnosis of post-COVID-19 sarcopenia
排除标准
- •Under medication
- •History of lower limb surgeries, fractures
- •Cardiac problems
- •Respiratory problems
- •Neurological problems
- •Systemic problems and any other contraindications for aerobic training
结局指标
主要结局
Handgrip strength
时间窗: 8 weeks
It is a simple and cost-effective test to measure the upper limb strength
次要结局
未报告次要终点
研究者
Marwa Eid
assistant professor of physical therapy for surgery
Cairo University
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Integrated Physical Training With Protein Diet in Older Adults With Sarcopenia Symptoms.SarcopeniaNCT05224453Prince Sattam Bin Abdulaziz University76
终止
不适用
Sarcopenia and Related Factors in Coronavirus Disease 2019 (COVID-19) Following Intensive CareSarcopeniaCovid19Intensive Care Unit Acquired WeaknessNCT05474157Koç University30
Unknown
不适用
Sarcopenia Studies for the Elderly Population in TaiwanSarcopeniaNCT00174135National Taiwan University Hospital100
尚未招募
不适用
Feasibility of Proteomics in Chronic Lung Disease With SarcopeniaSarcopeniaChronic Lung DiseaseNCT06312774University College, London49
Unknown
3 期
Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 VirusCOVID - 19NCT04355052Sheba Medical Center250